Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

138.80 +0.44 (+0.32%)

Streaming Delayed Price Updated: 3:13 PM EDT, Aug 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

77 78 Next >

Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares? ↗

March 27, 2025

The FDA is due to make an approval decision in mid-September for a key product from the top pharma company.

Via Investor's Business Daily

No Quick Fix For This Market ↗

March 23, 2025

Despite the pullback, we have found numerous opportunities which we discuss in this video using technical analysis.

Via Talk Markets

Topics Stocks / Equities

The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Experts ↗

March 11, 2025

Via Benzinga

Gilead Sciences's Options: A Look at What the Big Money is Thinking ↗

March 10, 2025

Via Benzinga

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

March 21, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its...

Via StockStory

Topics Artificial Intelligence

Which S&P500 stocks are gapping on Thursday? ↗

March 20, 2025

Let's have a look at the S&P500 gap up and gap down stocks in today's session.

Via Chartmill

Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed ↗

March 20, 2025

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.

Via Stocktwits

Stay informed with the top movers within the S&P500 index on Wednesday. ↗

March 19, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Explore the top gainers and losers within the S&P500 index in today's session. ↗

March 19, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Which S&P500 stocks are gapping on Wednesday? ↗

March 19, 2025

Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.

Via Chartmill

Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding ↗

March 19, 2025

HIV prevention is a staple in Gilead Sciences' wheelhouse.

Via Investor's Business Daily

Wednesday's pre-market session: top gainers and losers in the S&P500 index ↗

March 19, 2025

Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.

Via Chartmill

Crypto Mixed Post Trump-Putin Call; Trump Eyes HIV Program Cuts, Gilead Dips; Nvidia's AI Lead Secure Through 2028, Says JPMorgan – Top Headlines While The U.S. Slept ↗

March 19, 2025

Via Benzinga

Topics Artificial Intelligence Government

Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides ↗

March 19, 2025

HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the...

Via Benzinga

Topics Government

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

March 19, 2025

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Via StockStory

Topics Artificial Intelligence

Unpacking the Latest Options Trading Trends in Gilead Sciences ↗

March 18, 2025

Via Benzinga

Gilead Sciences - Leader In HIV Medicines ↗

March 14, 2025

The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline.

Via Talk Markets

Topics Stocks / Equities

Friday's session: top gainers and losers in the S&P500 index ↗

March 14, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Is Gilead Sciences Gaining or Losing Market Support? ↗

March 13, 2025

Via Benzinga

GILEAD SCIENCES INC (NASDAQ:GILD) Exhibits Quality Stock Traits. Here's Why. ↗

March 13, 2025

A fundamental analysis of (NASDAQ:GILD): Why GILEAD SCIENCES INC (NASDAQ:GILD) should be investigated by quality investors.

Via Chartmill

Gilead Presents New HIV Treatment And Cure Research Data ↗

March 12, 2025

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety in early HIV treatment.

Via Benzinga

Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option

March 12, 2025

From Gilead Sciences, Inc.

Via Business Wire

First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

March 11, 2025

From Gilead Sciences, Inc.

Via Business Wire

These 3 Dividend Stocks Jumped 15% in a Month—More to Come?

March 11, 2025

Via MarketBeat

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 11, 2025

Via Benzinga

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

March 11, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad...

Via StockStory

Topics Artificial Intelligence

The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI) ↗

March 11, 2025

Via The Motley Fool

Topics Artificial Intelligence

1 Value Stock with Exciting Potential and 2 to Ignore

March 10, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Best And Worst Performing S&P 500 Stocks Since Trump's Election Win ↗

March 07, 2025

Financial markets volatile since Trump's 2024 election, some companies surged like Palantir while others struggled such as First Solar.

Via Benzinga

Topics Government Stocks

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

77 78 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.